InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Vertex Pharmaceuticals

VRTX Clue Score74
United States Fiscal year ends December CIK 0000875320 Results filed 2 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

42
Insider
Date
Role
Action
Shares
Price
Amount
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
4,237
$471.43
$2.00M
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
11,712
$470.54
$5.51M
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
7,241
$469.61
$3.40M
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
19,662
$468.57
$9.21M
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
10,263
$467.75
$4.80M
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
1,848
$465.80
$860.80K
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
2,730
$465.05
$1.27M
Amit Sachdev
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
920
$463.91
$426.80K
Charles F Wagner Jr
6 Jan 2026
EVP, Co & Fo
Sold after exercise
9,532
$461.00
$4.39M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
2,070
$455.22
$942.31K
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
10,360
$453.34
$4.70M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
15,681
$452.20
$7.09M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
5,809
$451.20
$2.62M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
5,880
$449.84
$2.65M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
2,320
$448.78
$1.04M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
1,152
$447.05
$515.00K
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
7,899
$445.56
$3.52M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
4,352
$444.36
$1.93M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
2,469
$443.21
$1.09M
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
1,320
$441.26
$582.46K
Jeffrey M Leiden
3 Dec 2025
Executive Chairman
Sold after exercise
4,469
$440.40
$1.97M
Jeffrey M Leiden
14 Nov 2025
Executive Chairman
Sold after exercise
40
$442.00
$17.68K
Jeffrey M Leiden
14 Nov 2025
Executive Chairman
Sold after exercise
21,330
$441.35
$9.41M
Jeffrey M Leiden
14 Nov 2025
Executive Chairman
Sold after exercise
32,234
$440.30
$14.19M
Jeffrey M Leiden
13 Nov 2025
Executive Chairman
Sold after exercise
1,160
$441.05
$511.62K
Jeffrey M Leiden
13 Nov 2025
Executive Chairman
Sold after exercise
18,528
$440.22
$8.16M
Sangeeta N. Bhatia
30 Aug 2024
Director
Sold after exercise
646
$500.00
$323.00K
Sangeeta N. Bhatia
8 Aug 2024
Director
Sold after exercise
1,292
$466.29
$602.45K
Bruce I Sachs
1 Aug 2024
Director
Sold after exercise
5,295
$508.00
$2.69M
Reshma Kewalramani
24 May 2024
CEO & President
Sold after exercise
1,565
$457.00
$715.21K
Bruce I Sachs
22 May 2024
Director
Sold after exercise
7,073
$448.00
$3.17M
Reshma Kewalramani
15 Dec 2023
CEO & President
Sold after exercise
17,135
$407.00
$6.97M
Stuart A Arbuckle
13 Dec 2023
EVP, COO
Sold after exercise
8,603
$399.00
$3.43M
Bruce I Sachs
6 Nov 2023
Director
Sold after exercise
11,250
$385.00
$4.33M
Terrence C Kearney
10 Aug 2023
Director
Sold after exercise
10,000
$350.00
$3.50M
Bruce I Sachs
17 Jul 2023
Director
Sold after exercise
3,842
$357.29
$1.37M
Bruce I Sachs
17 Jul 2023
Director
Sold after exercise
5,711
$356.75
$2.04M
Bruce I Sachs
17 Jul 2023
Director
Sold after exercise
1,697
$355.54
$603.35K
Stuart A Arbuckle
15 Jun 2023
EVP, COO
Sold after exercise
8,603
$349.00
$3.00M
Bruce I Sachs
12 Apr 2023
Director
Sold after exercise
8,026
$327.48
$2.63M
Bruce I Sachs
12 Apr 2023
Director
Sold after exercise
10,357
$326.46
$3.38M
Bruce I Sachs
12 Apr 2023
Director
Sold after exercise
2,917
$325.65
$949.92K
Showing 250 of 1,875 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 1,071
Amendments (4/A) skipped 3
Filings about a different issuer 2
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 213
Sales straight out of an exercise 899
Sales at will 751
Transactions with no price 0
Shares from compensation/vesting 8,011,477
Sales filed before the plan box existed 751
History held since 4 Oct 2006